Cartesian Therapeutics, Inc. Operating Lease, Payments
Cartesian Therapeutics, Inc. (RNAC) reported Operating Lease, Payments of $2.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-06
- Cartesian Therapeutics, Inc. operating lease, payments for the quarter ending 2026-06-30 was $1.18M, a 7.65% increase year-over-year.
- Cartesian Therapeutics, Inc. operating lease, payments for the quarter ending 2026-03-31 was $1.17M, a 268.77% increase year-over-year.
- Cartesian Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $1.14M, a 12.27% increase year-over-year.
- Cartesian Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $1.11M, a 17.80% increase year-over-year.
- Cartesian Therapeutics, Inc. operating lease, payments for fiscal 2025 was $3.66M, a 2.89% increase from fiscal 2024.
- Cartesian Therapeutics, Inc. operating lease, payments for fiscal 2024 was $3.56M, a 32.01% increase from fiscal 2023.
- Cartesian Therapeutics, Inc. operating lease, payments for fiscal 2023 was $2.70M, a 31.64% increase from fiscal 2022.
- Cartesian Therapeutics, Inc. operating lease, payments for fiscal 2022 was $2.05M, a 13.02% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.35M 10-Q · filed 2026-08-06 | $3.49M derived: sum of 3 quarters · filed 2026-08-06 | $4.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.17M 10-Q · filed 2026-04-30 | $2.30M derived: sum of 2 quarters · filed 2026-04-30 | $3.42M derived: sum of 3 quarters · filed 2026-04-30 | $4.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.25M derived: sum of 2 quarters · filed 2026-03-09 | $3.35M derived: sum of 3 quarters · filed 2026-08-06 | $3.66M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.21M derived: sum of 2 quarters · filed 2026-08-06 | $2.53M 10-Q · filed 2025-11-06 | $3.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.42M 10-Q · filed 2026-08-06 | $2.43M derived: sum of 3 quarters · filed 2026-08-06 | $3.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $317.00K 10-Q · filed 2026-04-30 | $1.33M derived: sum of 2 quarters · filed 2026-04-30 | $2.27M derived: sum of 3 quarters · filed 2026-04-30 | $3.12M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.96M derived: sum of 2 quarters · filed 2026-03-09 | $2.80M derived: sum of 3 quarters · filed 2026-03-09 | $3.56M 10-K · filed 2026-03-09 |
| 2024-09-30 | $944.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.79M derived: sum of 2 quarters · filed 2025-11-06 | $2.55M 10-Q · filed 2025-11-06 | $3.25M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $843.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.60M 10-Q · filed 2025-08-07 | $2.31M derived: sum of 3 quarters · filed 2025-08-07 | $2.98M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $761.00K 10-Q · filed 2025-05-08 | $1.47M derived: sum of 2 quarters · filed 2025-05-08 | $2.14M derived: sum of 3 quarters · filed 2025-05-08 | $2.80M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $705.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.38M derived: sum of 2 quarters · filed 2025-03-13 | $2.04M derived: sum of 3 quarters · filed 2025-03-13 | $2.70M 10-K · filed 2025-03-13 |
| 2023-09-30 | $672.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.34M derived: sum of 2 quarters · filed 2024-11-07 | $1.99M 10-Q · filed 2024-11-07 | $2.64M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $666.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.32M 10-Q · filed 2024-08-08 | $1.97M derived: sum of 3 quarters · filed 2024-08-08 | $2.44M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $653.00K 10-Q · filed 2024-05-08 | $1.31M derived: sum of 2 quarters · filed 2024-05-08 | $1.78M derived: sum of 3 quarters · filed 2024-05-08 | $2.24M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $653.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $1.12M derived: sum of 2 quarters · filed 2024-03-07 | $1.59M derived: sum of 3 quarters · filed 2024-03-07 | $2.05M 10-K · filed 2024-03-07 |
| 2022-09-30 | $471.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $938.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.40M 10-Q · filed 2023-11-13 | $1.85M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $467.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-17 | $924.00K 10-Q · filed 2023-08-17 | $1.38M derived: sum of 3 quarters · filed 2023-08-17 | $1.84M derived: sum of 4 quarters · filed 2023-08-17 |
| 2022-03-31 | $457.00K 10-Q · filed 2023-05-04 | $914.00K derived: sum of 2 quarters · filed 2023-05-04 | $1.37M derived: sum of 3 quarters · filed 2023-05-04 | $1.82M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $457.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $914.00K derived: sum of 2 quarters · filed 2023-03-02 | $1.37M derived: sum of 3 quarters · filed 2023-03-02 | $1.81M 10-K · filed 2023-03-02 |
| 2021-09-30 | $457.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $911.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.35M 10-Q · filed 2022-11-03 | $1.80M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $454.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $898.00K 10-Q · filed 2022-08-08 | $1.34M derived: sum of 3 quarters · filed 2022-08-08 | $2.60M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $444.00K 10-Q · filed 2022-05-05 | $888.00K derived: sum of 2 quarters · filed 2022-05-05 | $2.14M derived: sum of 3 quarters · filed 2022-05-05 | $2.48M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $444.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.70M derived: sum of 2 quarters · filed 2022-03-10 | $2.04M derived: sum of 3 quarters · filed 2022-03-10 | $2.52M 10-K · filed 2022-03-10 |
| 2020-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.59M derived: sum of 2 quarters · filed 2021-11-09 | $2.08M 10-Q · filed 2021-11-09 | $2.45M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $338.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $825.00K 10-Q · filed 2021-08-12 | $1.20M derived: sum of 3 quarters · filed 2021-08-12 | $1.57M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $487.00K 10-Q · filed 2021-05-13 | $861.00K derived: sum of 2 quarters · filed 2021-05-13 | $1.23M derived: sum of 3 quarters · filed 2021-05-13 | $1.61M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $374.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $747.00K derived: sum of 2 quarters · filed 2021-03-12 | $1.12M derived: sum of 3 quarters · filed 2021-03-12 | $1.48M 10-K · filed 2021-03-12 |
| 2019-09-30 | $373.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $745.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.11M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $372.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $735.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $363.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |